Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Unknown 2Enrolling by invitation 1Completed 1

Sponsor Class

INDUSTRY 507OTHER 500NETWORK 26NIH 24OTHER_GOV 13UNKNOWN 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other neoplasm 1Breast 1

Conditions

Locally Advanced Malignant Neoplasm 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11Radiotherapy, Intensity-Modulated 9apatinib 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Drug Therapy 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Radiation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
UNKNOWN × Pemetrexed × Clear all
NCT04762459 2022-02-24

APEX

ChineseAMS

Phase 3 Enrolling by invitation
606 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

NCT02829008 2016-07-12

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

ChineseAMS

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT01143974 2013-03-14

Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer

ChineseAMS

Phase 4 Completed
28 enrolled
Other neoplasm

Locally Advanced Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡